Pomerantz LLP reminds investors in ADMA Biologics, Inc. that a class action lawsuit has been filed against the company and certain officers and directors over possible securities fraud. The deadline to seek appointment as lead plaintiff is August 10, 2026, for those who purchased or acquired ADMA securities during the class period. The suit follows a March 24, 2026, short report by Culper Research alleging ADMA's growth was driven by channel stuffing and an undisclosed related party distributor, causing the stock to fall $2.26 per share, or 16.63%, to $11.33. Two days later, Cantor Fitzgerald downgraded ADMA, citing a disappointing response to the report, and the stock fell another $1.34 per share, or 13.91%, to $8.29.
ADMA Biologics IncClass action lawsuit for securities fraud and Culper Research short report alleging channel stuffing and undisclosed related party distributor.